| Literature DB >> 23010377 |
Stephanie M Topp1, Michelle S Li, Julien M Chipukuma, Matimba M Chiko, Evelyn Matongo, Carolyn Bolton-Moore, Stewart E Reid.
Abstract
INTRODUCTION: Building on earlier works demonstrating the effectiveness and acceptability of provider-initiated counselling and testing (PITC) services in integrated outpatient departments of urban primary healthcare clinics (PHCs), this study seeks to understand the relative utility of PITC services for identifying clients with early-stage HIV-related disease compared to traditional voluntary testing and counselling (VCT) services. We additionally seek to determine whether there are any significant differences in the clinical and demographic profile of PITC and VCT clients.Entities:
Mesh:
Year: 2012 PMID: 23010377 PMCID: PMC3494161 DOI: 10.7448/IAS.15.2.17352
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Clinic characteristics of nine integrated urban primary health care facilities
| Integrated Clinics | ART | ART | Catchment population (2010) | Approx. daily outpatient attendance | Ever enrolled (b/f 1 July 2011) | PITC | VCT |
|---|---|---|---|---|---|---|---|
| Clinic 1 | Jan 2005 | Nov 2008 | 52,549 | 100 | 3,822 | 337 | 1014 |
| Clinic 2 | Feb 2009 | Feb 2009 | 18,050 | 45 | 1,907 | 263 | 1364 |
| Clinic 3 | Aug 2004 | Apr 2010 | 74,116 | 180 | 13,032 | 92 | 1,339 |
| Clinic 4 | May 2008 | Oct 2009 | 47,904 | 95 | 3,987 | 489 | 1,370 |
| Clinic 5 | Mar 2007 | Jun 2010 | 28,979 | 60 | 4,896 | 51 | 1,038 |
| Clinic 6 | Jul 2006 | Apr 2009 | 70,219 | 120 | 7,057 | 546 | 1,928 |
| Clinic 7 | Mar 2007 | Jul 2008 | 31,872 | 80 | 3,802 | 461 | 1,677 |
| TOTAL | – | – | 323,689 | 680 | 38,503 | 2239 | 9730 |
Includes clients referred from TB Department and Maternal & Child Health Department; b/f=before.
VCT and PITC cohort numbers represent those enrolled from the date of integration at each clinic through to 1 July 2011. Only clients newly enrolled from the date that ART was integrated in each clinic were included; clients enrolled before this date are automatically excluded.
Baseline demographic and clinical characteristics for clients accessing HIV treatment in nine integrated clinics via PITC and VCT
| Characteristics | PITC | VCT |
|
|---|---|---|---|
| Age |
|
| |
| At enrolment | 32.0 (26.0–39.0) | 32.0 (26.0–38.0) | 0.5429 |
| ≤15 | 225 (10.0%) | 719 (7.4%) | <0.0001 |
| 16–35 | 1193 (53.3%) | 5617 (57.7%) | . |
| 36+ | 821 (36.7%) | 3394 (34.9%) | . |
| Sex |
|
| |
| Female | 1261 (56.3%) | 5868 (60.0%) | 0.0005 |
| Male | 978 (43.7%) | 3862 (40.0%) | . |
|
|
| ||
| CD4 (cells/µL) at enrolment | 224 (110.0–387.0) | 264 (137.0–427.0) | <0.0001 |
| ≤50 | 223 (11.2%) | 701 (8.3%) | <0.0001 |
| 51–199 | 676 (33.8%) | 2561 (30.1%) | . |
| 200–349 | 514 (25.7%) | 2195 (25.8%) | . |
| ≥350 | 585 (29.3%) | 3049 (35.8%) | . |
|
|
| ||
| BMI (kg/m2) at enrolment | 20.0 (18.1–22.2) | 20.4 (18.4–22.8) | <0.0001 |
| <18.5 | 559 (28.9%) | 2196 (25.5%) | <0.001 |
| 18.5–24.99 | 1180 (61.1%) | 5357 (62.3%) | . |
| ≥25 | 193 (10.0%) | 1049 (12.2%) | . |
|
|
| ||
| HBG (g/dL) at enrolment | 11.2 (9.7–12.6) | 11.7 (10.1–13.2) | <0.0001 |
| ≤8 | 163 (8.4%) | 539 (6.5%) | <0.0001 |
| 8.1–9.9 | 388 (19.9%) | 1420 (17.0%) | . |
| ≥10 | 1400 (71.8%) | 6380 (76.5%) | . |
| Active TB at enrolment |
|
| |
| Yes | 113 (5.0%) | 99 (1.0%) | <0.0001 |
| No | 2126 (95.0%) | 9631 (99.0%) | . |
| Education |
|
| |
| None | 809 (36.2%) | 2503 (27.5%) | <0.0001 |
| Primary | 674 (30.2%) | 2919 (32.1%) | . |
| Secondary and tertiary | 751 (33.6%) | 3670 (40.4%) | . |
| Partner HIV status |
|
| |
| Negative | 93 (4.2%) | 500 (5.1%) | <0.0001 |
| Positive | 376 (16.8%) | 2611 (26.8%) | . |
| Unknown/missing | 1770 (79.1%) | 6619 (68.0%) | . |
PITC=Clients who tested positive to HIV in provider-initiated testing services available in an integrated clinic and subsequently enrolled in HIV care up to study cut-off date.
VCT=Clients who tested positive to HIV in any (on-site or off-site) voluntary HIV testing services and enrolled in HIV care in an integrated clinic, up to study cut-off date.
Wilcoxon rank-sum tests.
Pearson's Chi-square test.
Education level, partner serostatus and active TB among male and female PITC and VCT Clients
| Sex | Education status |
| ||
|---|---|---|---|---|
| Male | No education | 330 (34%) | 922 (26%) | <0.0001 |
| Primary | 268 (27%) | 977 (27%) | ||
| Secondary | 378 (39%) | 1701 (47%) | ||
| Female | No education | 479 (38%) | 1581 (29%) | <0.0001 |
| Primary | 406 (32%) | 1942 (35%) | ||
| Secondary | 373 (30%) | 1969 (36%) | ||
| Partner HIV status | PITC (%) | VCT (%) | ||
| Male | Negative | 61 (6%) | 284 (7%) | <0.0001 |
| Positive | 203 (21%) | 1293 (33%) | ||
| Unknown or missing | 714 (73%) | 2285 (59%) | ||
| Female | Negative | 32 (3%) | 216 (4%) | <0.0001 |
| Positive | 173 (14%) | 1318 (22%) | ||
| Unknown or missing | 1056 (84%) | 4334 (74%) | ||
| Active TB at enrolment | PITC (%) | VCT (%) | ||
| Male | No TB | 914 (93%) | 3821 (99%) | <0.0001 |
| Active TB | 64 (7%) | 41 (1%) | ||
| Female | No TB | 1212 (96%) | 5810 (99%) | <0.0001 |
| Active TB | 49 (4%) | 58 (1%) | ||
PITC=Clients who tested positive to HIV in provider-initiated testing services available in an integrated clinic and subsequently enrolled in HIV care up to study cut-off date.
VCT=Clients who tested positive to HIV in any (on-site or off-site) voluntary HIV testing services and enrolled in HIV care in an integrated clinic, up to study cut-off date.
Pearson's Chi-square test.
Outcomes for PITC and VCT clients across four clinical management indicators
| Programmatic outcomes | Number of clients | Crude odds ratio |
| Adjusted odds ratio |
|
|---|---|---|---|---|---|
| Dead in 90 days | |||||
| VCT | 155/8680 (1.8%) | Referent | Referent | ||
| PITC | 75/2239 (3.3%) | 1.91 (1.44–2.52) | <.001 | 1.36 (0.94–1.96) | 0.100 |
| Initiated on ART if eligible | |||||
| VCT | 4523/6520 (69.4%) | Referent | Referent | ||
| PITC | 1187/1655 (71.7%) | 1.12 (0.99–1.26) | 0.063 | 0.90 (0.82–0.97) | 0.010 |
| Time to ART initiation<4 weeks (among those who initiated) | |||||
| VCT | 2828/4523 (62.5%) | Referent | Referent | ||
| PITC | 665/1187 (56.0%) | 0.76 (0.67–0.87) | <.001 | 0.86 (0.75–0.99) | 0.035 |
| Retained in care at 6 months | |||||
| VCT | 3765/6079 (61.9%) | Referent | Referent | ||
| PITC | 1105/1929 (57.3%) | 0.82 (0.74–0.91) | <.001 | 0.84 (0.74–0.95) | 0.004 |
| MPR | |||||
| VCT | 1604/2880 (55.7%) | Referent | Referent | ||
| PITC | 543/933 (58.2%) | 1.11 (0.95–1.29) | 0.180 | 1.00 (0.79–1.27) | 0.982 |
Denominator for those included in programmatic outcome includes those with sufficient follow-up time and those with data available in the electronic medical record. For example, MPR<95 after six months on ART was assessed amongst those initiated on ART for at least six months within the time parameters. Additionally, since the study relied on routinely collected data some clients had missing data excluding them from analysis.
Dead in 90 Days=clients recorded as dead within 90 days of enrolling in HIV care and treatment.
VCT=Clients who tested positive to HIV in any (on-site or off-site) voluntary HIV testing services and enrolled in HIV care in an integrated clinic, up to study cut-off date.
PITC=Clients who tested positive to HIV in provider-initiated testing services available in an integrated clinic and subsequently enrolled in HIV care up to study cut-off date.
Initiated on ART if eligible=clients enrolled in HIV care and treatment and initiated on antiretroviral therapy if eligible according to Zambian national guidelines.
MPR=Medication possession ratio, an estimation of client adherence to individual antiretroviral drug regime.
Crude odds ratios (ORs) and 95% confidence intervals (95% CIs) computed using logistic regression models to assess the relationship between testing group and the five programmatic outcomes.
Adjusted odds ratios (AORs) and their corresponding 95% CIs generated using generalized estimating equations to account for clustering by site; adjusted for age, sex, CD4 cell count, BMI, HGB, TB status at enrolment, education level and partner HIV status.